News

CVS Health reportedly excludes coverage for Gilead’s new HIV drug for now

CVS Health (CVS) won't include Gilead's (GILD) new HIV drug Yeztugo in its commercial healthcare plans, due to clinical, regulatory and financial factors. Read more here.
Stocktwits on MSN10h

CVS Health Reportedly Keeps Gilead’s New HIV Preventative Shot Off Its Plans, Faces $290M Medicare Fraud Ruling

CVS Health, which operates the largest U.S. pharmacy benefit manager, will not add Gilead Sciences’ new HIV prevention drug ...

Exclusive-CVS holds off adding Gilead’s new HIV prevention shot to drug coverage lists

By Deena Beasley (Reuters) -CVS Health, which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' ...

CVS Health won’t cover Gilead’s new HIV prevention drug Yeztugo - Reuters

Investing.com -- CVS Health (NYSE: CVS) will not include Gilead Sciences (NASDAQ: GILD )’ new HIV prevention drug Yeztugo in its commercial plans for the time being, despite the medication’s proven ...